Transplant center directory

Our institute provides care to patients receiving autologous, related and unrelated allogeneic, cord blood and mismatched stem cell transplants. Research efforts are aimed at preventing and treating graft-versus-host disease, targeting patient immune cells to kill cancer cells and chemotherapy dose escalation for the treatment of hematological cancers.

This center has been performing allogeneic transplants since 1987 and has been an NMDP/Be The Match transplant center since August 1992.

This center's actual 1-year survival results are below the expected rate for this center.

The survival information we have for this center includes ONLY:

1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2019, 2020, 2021, and
2. Who had their transplant at a U.S. transplant center, and
3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 285 patients.

The actual 1-year survival of these patients is 65.2%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 65.5% and 75.6%.

For help with understanding these statistics, please see Understanding Transplant Outcomes.

For overall survival for all patients transplanted with a specific disease, please see U.S. Patient Survival report at bloodcell.transplant.hrsa.gov.

All diseases

Number of transplants by age reported from January 1, 2021 to December 31st, 2022 (includes marrow, PBSC and cord blood)

Treatments may be similar for diseases within a group. It might be helpful to look at centers that have done transplants for a specific disease and centers that have done transplants for any corresponding broad disease categories.